SCHEMBL13320541

SCHEMBL13320541

CC(=O)c1ncn([C@@H]2O[C@H](CO)C(O)[C@@H]2O)n1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.76
▸ SMN1; SMN2 Q16637 3/20 0.76
▸ ALDH1A1 P00352 3/20 0.76
▸ TSHR P16473 2/20 0.76
▸ THPO P40225 2/20 0.76
▸ PMP22 Q01453 2/20 0.76
▸ GLA P06280 1/20 0.76
▸ EIF4E P06730 1/20 0.76
▸ CYP3A4 P08684 1/20 0.76
▸ TOP1 P11387 1/20 0.76
▸ ADORA1 P30542 1/20 0.76
▸ PNP P00491 3/20 0.68
▸ KDM4E B2RXH2 2/20 0.47
▸ HTT P42858 2/20 0.47
▸ BLM P54132 2/20 0.47
▸ TP53 P04637 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ GMNN O75496 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13352082 1.00 LMNA (0.76) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL13320671 1.00 LMNA (0.76) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL12901991 1.00 LMNA (0.76) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL2845582 1.00 LMNA (0.76) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL15617567 0.89 LMNA (0.61) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL5566208 0.88 LMNA (0.78) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL15155278 0.88 LMNA (0.78) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL4195683 0.88 LMNA (0.78) LMNASMN1; SMN2ALDH1A1TSHRTHPO
Ribavirin SCHEMBL28339185 0.87 LMNA (0.90) LMNASMN1; SMN2ALDH1A1TSHRTHPO
Ribavirin SCHEMBL4064991 0.86 LMNA (1.00) LMNASMN1; SMN2ALDH1A1TSHRTHPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11786542-B2 Methods for enhancing cytotoxic cancer therapy through modulation of purine biosynthesis pathways NORTHWESTERN UNIVERSITY (US) 2023-10-17 — — US disclosed
US-20100129317-A1 AZOLE NUCLEOSIDES AND USE AS INHIBITORS OF RNA AND DNA VIRAL POLYMERASES SOUTHERN RESEARCH INSTITUTE (US) 2010-05-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11786542-B2 Methods for enhancing cytotoxic cancer therapy through modulation of purine biosynthesis pathways IMPDH1, IMPDH2, AMPD3 LMNA 3194/4885SMN1; SMN2 2108/4885ALDH1A1 97/4885
US-20100129317-A1 AZOLE NUCLEOSIDES AND USE AS INHIBITORS OF RNA AND DNA VIRAL POLYMERASES RNASEH1, RNASEL, POLR2E LMNA 739/4885SMN1; SMN2 3616/4885ALDH1A1 2684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback